Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ES019
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Astellas Pharma
Deal Size : $1,737.0 million
Deal Type : Collaboration
Details : The collaboration aims to conduct early-stage research for novel bi-specific macrophage engagers, ES019, an anti-PD-L1/SIRPα bispecific antibody, and another program.
Brand Name : ES019
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 27, 2023
Lead Product(s) : ES019
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Astellas Pharma
Deal Size : $1,737.0 million
Deal Type : Collaboration
Details : ES009 specifically binds to a unique epitope on human LILRB2 and potently blocks LILRB2 binding to multiple ligands, which is investigated for the treatment of cancer.
Brand Name : ES009
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 26, 2023
Details : ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME).
Brand Name : ES014
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 27, 2023
Details : ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways to synergistically activates T cells for ICB-resistant cancer immunotherapy
Brand Name : ES014
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 22, 2022
Lead Product(s) : ES005
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models.
Brand Name : ES005
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 21, 2022
Lead Product(s) : ES005
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ES014
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment.
Brand Name : ES014
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 09, 2022
Lead Product(s) : ES014
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asciminib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers
Details : ES104 (asciminib) demonstrated, 42% overall response rate (ORR) based on 10 patients with Partial Responses (PRs), including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation.
Brand Name : ES104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 05, 2022
Lead Product(s) : Asciminib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ES002
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Greater Bay Area Homeland Development Fund
Deal Size : $105.0 million
Deal Type : Series C Financing
Elpiscience Announces the Completion of $105 Million Series C Financing
Details : ES002, a potentially best-in-class anti-CD39 antibody, binds to CD39 with sub-nanomolar binding affinity and effectively blocks CD39 ATPase activity. ES002 exhibits a strong efficacy in tumor growth inhibition in vivo.
Brand Name : ES002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 13, 2021
Lead Product(s) : ES002
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Greater Bay Area Homeland Development Fund
Deal Size : $105.0 million
Deal Type : Series C Financing
Details : Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territor...
Brand Name : ABL001
Molecule Type : Large molecule
Upfront Cash : $7.0 million
January 20, 2021
LOOKING FOR A SUPPLIER?